1,102 results

#125712-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

Jan. 8, 2025

Academic Institutions and Nonprofits only

#104495-PHPeB

Ready-to-use AAV PHP.eB particles produced from pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE (#104495). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE plasmid DNA. CAG-driven, Cre-dependent GCaMP7s calcium sensor. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Feb. 5, 2024

Academic Institutions and Nonprofits only

#198516-AAV5

Ready-to-use AAV5 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#159605-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-NIR-GECO2G (#159605). In addition to the viral particles, you will also receive purified pAAV-CAG-NIR-GECO2G plasmid DNA. CAG-driven expression of the near-infrared calcium indicator NIR-GECO2G. These AAV preparations are suitable purity for injection into animals.

Robert Campbell

Qian et al PLoS Biol. 2020 Nov 24;18(11):e3000965.

Dec. 18, 2024

Academic Institutions and Nonprofits only

#232837-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-NES-SomaFRCaMPi (#232837). In addition to the viral particles, you will also receive purified pAAV-Syn-NES-SomaFRCaMPi plasmid DNA. Synapsin-driven SomaFRCaMPi calcium sensor. These AAV preparations are suitable purity for injection into animals.

Kiryl Piatkevich

Zhou et al PLoS Biol. 2025 Apr 29;23(4):e3003048. d

Jan. 15, 2026

Academic Institutions and Nonprofits only

#214869-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP15140: pAAV-AiE0873m_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN5140) (#214869). In addition to the viral particles, you will also receive purified AiP15140: pAAV-AiE0873m_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN5140) plasmid DNA. minBG-driven expression of CoChR-EGFP in striatal cholinergic neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#115892-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-Archon1-KGC-GFP-ER2 (#115892). In addition to the viral particles, you will also receive purified pAAV-Syn-Archon1-KGC-GFP-ER2 plasmid DNA. Syn-driven Archon1, an opsin-based fluorescent voltage indicator, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Piatkevich et al Nat Chem Biol. 2018 Feb 26. pii: 10.1038

Feb. 28, 2019

Academic Institutions and Nonprofits only

#203841-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-Kir2.1Mut-2A-mScarlet-KASH (#203841). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1Mut-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of mutant murine Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Feb. 9, 2026

Academic Institutions and Nonprofits only

#203840-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH (#203840). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Feb. 6, 2026

Academic Institutions and Nonprofits only

#104055-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#121539-AAVrg

Ready-to-use AAV Retrograde particles produced from pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) (#121539). In addition to the viral particles, you will also receive purified pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) plasmid DNA. Synapsin-driven, HA-tagged hM3D(Gq) for neuronal activation. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Aug. 7, 2025

Academic Institutions and Nonprofits only

#59133-AAV1

Ready-to-use AAV1 particles produced from pOTTC589 - pAAV c-fos Nuc-eYFP (#59133). In addition to the viral particles, you will also receive purified pOTTC589 - pAAV c-fos Nuc-eYFP plasmid DNA. C-fos-driven expression of Nuc-eYFP. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Richie et al J Neurosci Methods. 2017 Jun 1;284:1-14.

Jan. 15, 2026

Academic Institutions and Nonprofits only

#198510-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-mScarlet-WPRE (#198510). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#176757-AAV1

Ready-to-use AAV1 particles produced from AAV-EF1a-jGCaMP8m-WPRE (#176757). In addition to the viral particles, you will also receive purified AAV-EF1a-jGCaMP8m-WPRE plasmid DNA. EF1a-driven expression of calcium sensor GCaMP8m. These AAV preparations are suitable purity for injection into animals.

Loren Looger

July 12, 2023

Academic Institutions and Nonprofits only

#190155-AAV1

Ready-to-use AAV1 particles produced from AAV_pMBP-EGFP-caax (#190155). In addition to the viral particles, you will also receive purified AAV_pMBP-EGFP-caax plasmid DNA. MBP-driven EGFP expression in oligodendrocytes. These AAV preparations are suitable purity for injection into animals.

Brad Zuchero

Lam et al Nat Commun. 2022 Sep 23;13(1):5583. doi:

Jan. 15, 2026

Academic Institutions and Nonprofits only

#58892-AAV5

Ready-to-use AAV5 particles produced from pAAV-GFAP104-ChR2-mCherry (#58892). In addition to the viral particles, you will also receive purified pAAV-GFAP104-ChR2-mCherry plasmid DNA. GFAP -driven, expression of humanized ChR2 H134R mutant fused to mCherry, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Perea et al Nat Commun. 2014;5:3262. doi: 10.1038/nc

Jan. 14, 2026

Academic Institutions and Nonprofits only

#122100-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-GFP (#122100). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-GFP plasmid DNA. EF1a-driven expression of GFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#109048-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST (#109048). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST plasmid DNA. Cre-dependent expression of the anion channelrhodopsin GtACR1 fused to ER export signal and targeted to the neuronal soma and proximal dendrites, translated from an internal ribosomal entry site (IRES) following mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

Hillel Adesnik

Mardinly et al Nat Neurosci. 2018 Apr 30. pii: 10.1038/

Feb. 5, 2024

Academic Institutions and Nonprofits only

#37825-AAV11.T

Ready-to-use AAV11 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only

#210400-AAV2

Ready-to-use AAV2 particles produced from PRS_8-GCaMP8m (#210400). In addition to the viral particles, you will also receive purified PRS_8-GCaMP8m plasmid DNA. PRS-driven expression of calcium sensor GCaMP8m. These AAV preparations are suitable purity for injection into animals.

Simon Wiegert

Wissing et al PLoS Biol. 2025 Jul 7;23(7):e3003228. do

Feb. 6, 2026

Academic Institutions and Nonprofits only